SERAPHIN
2013
Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome
In 742 patients with pulmonary arterial hypertension, macitentan reduced morbidity and mortality events compared with placebo.
Result
Efficacy: First morbidity or mortality eventHR 0.55
Below 1 favours macitentan, above 1 favours placebo.
- Subtopic
- Endothelin antagonists
- Design
- Double-blind, event-driven RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC/ERS 2022 PH
- Source
- Pulido T, et al. N Engl J Med. 2013;369(9):809-818.doi 10.1056/NEJMoa1213917
Discussion & critique
First PAH trial powered for a long-term morbidity/mortality endpoint rather than 6-minute walk distance; it raised the evidentiary bar for the field.